Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer.

Yusuf IlhanAli Murat TatliFatih TekerArif Hakan OnderFatih KoseCaglayan GeredeliMustafa KaraagacMuhammet Ali KaplanMevlude InancSabin Goktas AydinAysegul KargiHacı ArakBanu OzturkAli Ayberk BesenOguzhan SelviMustafa KorkmazZeynep OrucOktay BozkurtAhmet BiliciSelami BayramShute Ailia DaeMustafa OzdoganHasan Senol CoskunSema Sezgin Goksu

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022)

There is no survival difference between cisplatin or carboplatin combined with paclitaxel and bevacizumab in metastatic or recurrent cervical cancer.

Keyphrases

metastatic colorectal cancer
squamous cell carcinoma
small cell lung cancer
phase ii study
phase iii
free survival
open label
rectal cancer
study protocol
placebo controlled